Successful CRISPR Epigenome Editing Reduces Knee and Jaw Joint Pain
The Hidden Cause of OA Pain: Inflammatory Cytokines
Joint pain in OA patients originates from inflammatory cytokines that hyper‑sensitize the nerves innervating the TMJ and knee. Conventional therapies only alleviate symptoms and do not address the underlying cause.
IL1R1 Suppression with CRISPR‑dCas9‑KRAB Restores Sensation
The research team engineered a CRISPR epigenome‑editing vector targeting IL1R1 and delivered it to femoral and trigeminal ganglion neurons. Neurons exposed to IL‑1β and OA cartilage displayed exaggerated calcium signals in response to heat, but DRG neurons recovered to baseline after editing, and TG neurons showed a reduction in maximal responses.
TMJ Sensation Not Fully Restored
In TG neurons, the proportion of sensitized cells did not return completely to normal, indicating that additional factors contribute. Therefore, a multi‑target approach will likely be required in the future.
Implications and Outlook
If this technology can be applied to human knee and jaw joint pain, it could achieve fundamental pain suppression without drug side effects. Widespread adoption of personalized gene‑regulation therapies is expected to markedly improve quality of life for OA patients.
PURPOSE: Osteoarthritis (OA) pain can arise from inflammatory cytokines sensitizing neurons that innervate the temporomandibular joint (TMJ) and knee. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based epigenome editing enables targeted repression of inflammatory receptors and offers a promising strategy to modify disease mechanisms. This study tested whether CRISPR epigenome editing of interleukin-1 receptor type 1 (IL1R1) in trigeminal ganglia (TG; TMJ-innervating) and dorsal root ganglia (DRG; knee-innervating) neurons could reduce OA-associated sensitization. METHODS: OA cartilage was collected from knee replacement patients and compared with healthy cadaveric cartilage. Rat TG and DRG neurons were cultured with IL-1β on tissue culture plastic or cartilage explants, loaded with calcium dye, and subjected to thermal stimulation. Neurons were transduced with lentiviral CRISPR-dCas9-KRAB vectors targeting IL1R1 or with nontargeting controls, and heat-evoked calcium transients were measured. RESULTS: Exposure to IL-1β and OA cartilage both increased the proportion of TG and DRG neurons exhibiting heat-induced calcium transients compared with controls. CRISPR epigenome editing of IL1R1 abolished sensitization in DRG neurons, restoring responses to healthy cartilage levels. In TG neurons, editing reduced maximum calcium responses to baseline but did not fully normalize the percentage of sensitized cells, suggesting additional OA factors contribute to TMJ pain. CONCLUSION: CRISPR epigenome editing of IL1R1 in joint-innervating neurons reduces OA cartilage-induced sensitization. These results highlight differential mechanisms underlying OA cartilage driven DRG and TG neuron sensitization and establish epigenome editing as a potential therapeutic strategy to target OA-associated sensitization in the knee and TMJ.
OA pain is driven by inflammatory cytokines that hyper‑sensitize nerves, severely limiting daily activities. The IL1R1 inhibition demonstrated in this study can fundamentally reduce pain without drugs, allowing everyone to move more comfortably.